Geriatric Assessment for Older Patients With Lung Cancer Provides No Survival Advantage

Share this content:
Treating older patients with advanced lung cancer on the basis of comprehensive geriatric assessments carried no survival advantage over performance status and age.
Treating older patients with advanced lung cancer on the basis of comprehensive geriatric assessments carried no survival advantage over performance status and age.

Treating older patients with advanced lung cancer on the basis of comprehensive geriatric assessments carried no survival advantage over performance status and age, according to a large European study.1 However, using these multidisciplinary assessments prior to chemotherapy resulted in fewer adverse side effects.

In this phase 3 trial, nearly 500 patients with stage 4 non-small cell lung cancer were randomly assigned to receive either chemotherapy based on performance status and age, or to chemotherapy based on scores from comprehensive geriatric assessments (CGA). Median age in the open-label, multicenter trial at 45 centers in France and Spain, was 77.

“In a non-curative setting such as this, you want to minimize toxicity, so this is important” Stuart Lichtman, MD, FACP, an attending physician and member, Memorial Sloan Kettering Cancer Center in New York, NY, told Cancer Therapy Advisor. Lichtman, who serves on the elderly cancer committee of the Alliance for Clinical Trials in Oncology, praised the investigators for designing the trial and said that accruing 494 patients so quickly between 2010 and 2013, was a “testament to their dedication and a monumental feat.”

Even though there was no improvement in survival, he said, the large amount of data generated by the study can be used in other ways, beyond its therapeutic findings, in the future.

In the standard arm of the trial, older patients under age 75, with a performance status of less than 1, or unable to do strenuous activities, received 2 carboplatin-based drugs. Those over 75 years or with a slightly worse performance status of 2, received just 1 chemotherapy drug, docetaxel.

RELATED: Lung Cancer Question-and-Answer Session With Gregory Masters, MD

Similarly, in the CGA arm, the most fit cancer patients with the best CGA scores also received 2 carboplatin-based drugs, while vulnerable patients received docetaxel alone and the frailest patients—about 24% of those enrolled in this arm—received best supportive care only.

The primary endpoint of the trial was treatment failure-free survival, defined as the time elapsing between random trial assignment and early treatment discontinuation as a result of any reason, including disease progression, treatment toxicity, or early death.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters